News tagged with bortezomib
Related topics: multiple myeloma
Bortezomib (INN, originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Sorry no news is found ... Your search criteria may have been too narrow. You can quickly re-sort the news in different ways by clicking on the tabs at the top of this page.